Research progress on the association between glycemic variability index derived from CGM and cardiovascular disease
Lei Zhang1,2, Xiao-Xuan Sun3,4, Qing-Shan Tian5
1The 1st Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330000, China.
Insights
Continuous glucose monitoring (CGM) offers superior insights into diabetes glycemic control over HbA1c. CGM parameters like time in range are linked to cardiovascular disease complications, guiding better patient care.
Area of Science:
- Endocrinology
- Cardiology
- Metabolic Diseases
Background:
- Glycated hemoglobin A1c (HbA1c) is a standard but limited measure of diabetes glycemic control.
- Continuous glucose monitoring (CGM) provides detailed, real-time glycemic data.
- Emerging CGM metrics like time in range (TIR), time above range (TAR), and time below range (TBR) offer new insights into glycemic variability.
Purpose of the Study:
- To comprehensively review the association between CGM-derived glycemic parameters and cardiovascular disease (CVD) complications.
- To provide scientific evidence for the standardized clinical application of CGM metrics.
- To guide better glycemic control strategies for preventing CVD in diabetes patients.
Main Methods:
- Systematic literature review of domestic and international studies.
- Analysis of research linking CGM parameters (TIR, TAR, TBR) to CVD complications.
- Evaluation of clinical data on glycemic fluctuation and patient outcomes.
Main Results:
- CGM-derived glycemic parameters are significantly associated with microvascular and macrovascular complications of diabetes.
- These metrics correlate with cardiovascular disease complications and prognosis.
- CGM data offers a more nuanced understanding of glycemic control than HbA1c alone.
Conclusions:
- CGM parameters are valuable indicators for assessing glycemic control and predicting CVD risk in diabetes.
- Standardized use of CGM metrics can improve clinical decision-making and patient outcomes.
- Further research and clinical integration of CGM are crucial for diabetes management and CVD prevention.
Abstract:
Currently, glycated hemoglobin A1c (HbA1c) has been widely used to assess the glycemic control of patients with diabetes. However, HbA1c has certain limitations in describing both short-term and long-term glycemic control. To more accurately evaluate the glycemic control of diabetes patients, the continuous glucose monitoring (CGM) technology has emerged. CGM technology can provide robust data on short-term glycemic control and introduce new monitoring parameters such as time in range, time above range, and time below range as indicators of glycemic fluctuation. These indicators are used to describe the changes in glycemic control after interventions in clinical research or treatment modifications in diabetes patient care. Recent studies both domestically and internationally have shown that these indicators are not only associated with microvascular complications of diabetes mellitus but also closely related to cardiovascular disease complications and prognosis. Therefore, this article aims to comprehensively review the association between CGM-based glycemic parameters and cardiovascular disease complications by analyzing a large number of domestic and international literature. The purpose is to provide scientific evidence and guidance for the standardized application of these indicators in clinical practice, in order to better evaluate the glycemic control of diabetes patients and prevent the occurrence of cardiovascular disease complications. This research will contribute to improving the quality of life for diabetes patients and provide important references for clinical decision-making.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Diabetes: Symptoms, Diagnosis, and Complications
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...


